Keywords
selective COX-2 inhibitor
Dibutyltin dichloride
Abstract
The search for new prophylactic and therapeutic drugs for the treatment of chronic pancreatitis (CP) is an urgent problem in current pancreatology. A promising direction in CP therapy may be the use of nonsteroidal anti-inflammatory drugs. Hence, the aim of the present study was to investigate the selective inhibition properties of COX-2 rofecoxib on the development of pancreas fibrosis in rats with experimental chronic pancreatitis induced by Dibutyltin dichloride (DBTC). The 60 male albino Wistar rats of our study were placed into three groups of 20 animals in each: I - the intact control; II - that which received an intraperitoneal injection (i.p.) of DBTC (6 mg/g); III - those which, 28 days after administration of DBTC (6 mg/g, i.p.), received a two-week course of treatment of rofecoxib (5 mg/kg, i.p). One day after rofecoxib treatment was completed, analysis was undertaken regarding the level of amylase, as well as the pancreatic amylase and lipase in the blood serum and the prostaglandin E2 in the pancreatic tissue. In addition, the morphological condition of the pancreas was ascertained. The obtained data suggest that administration of Rofecoxib reduces the development of fibrosis and improves the morpho-functional state of the pancreas in rats with chronic pancreatitis induced by DBTC. Thus, treatment with a selective COX-2 inhibitor could be a possible strategy for improving the clinical outcome of patients with CP.References
1. Bang U.C. et al.: Mortality, cancer, and comorbidities associated with chronic pancreatitis: A Danish nationwide matched-cohort study. Gastroenterol., 146, 989-994, 2014.
2. Braganza J.M. et al.: Chronic pancreatitis. Lancet, 377, 1184-1197, 2011.
3. Dumonceau J.M. et al.: Treatment for painful calcified chronic pancreatitis: extracorporeal shock wave lithotripsy versus endoscopic treatment: A randomised controlled trial. Gut, 56, 545-552, 2007.
4. Hashimoto T. et al.: Apoptosis of acinar cells is involved in chronic pancreatitis in WBN/Kob rats: Role of glucocorticoids. Pancreas, 21, 296-304, 2000.
5. Jimenez R.E. et al.: Outcome of pancreaticoduodenectomy with pylorus preservation or with antrectomy in the treatment of chronic pancreatitis. Ann Surg., 231, 293-300, 2000.
6. Kalady M.F. et al.: Immediate and long-term outcomes after lateral pancreaticojejunostomy for chronic pancreatitis. Am Surg., 67, 478-483, 2001.
7. Kono H. et al.: Development of an animal model of chronic alcoholinduced pancreatitis in the rat. Am J Physiol Gastrointest Liver Physiol., 280, 1178-1186, 2001.
8. Malka D. et al.: Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut, 51, 849-852, 2002.
9. Mydro A. et al.: RAS inhibitors decrease apoptosis of acinar cells and increase elimination of pancreatic stellate cells after in the course of experimental chronic pancreatitis induced by Dibutyltin Dichloride. J of Physiol. and Pharmacol., 59, 2, 239-249, 2008.
10. Nair R.J., Lawler L, Miller M.R.: Chronic pancreatitis. Am Fam Physician., 1, 76, 11, 1679-1688, 2007.
11. Otsuki M., Yamamoto M., Yamaguchi T.: Animal Models of Chronic Pancreatitis Gastroenterol. Research and Practice, 8 pages, 2010.
12. Reding T. et al.: A Selective COX-2 inhibitor suppresses chronic pancreatitis in an animal model (WBN/Kob rats): Significant reduction of macrophage infiltration and fibrosis. Gut, 55, 8, 1165-1173, 2006.
13. Strate T. et al.: Pathogenesis and the natural course of chronic pancreatitis. Eur J Gastroenterol Hepatol, 14, 929-934, 2002.
14. Wyatt J.E., Pettit W.L., Harirforoosh S.: Pharmacogenetics of nonsteroidal anti-inflammatory drugs. Pharmacogenomics J., 12, 6, 462-467, 2012.
15. Wang Luo-Wei et al.: Sonic hedgehog expression in a rat model of chronic pancreatitis. World J Gastroenterol., 28, 20, 16, 4712-4717, 2014.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Copyright (c) 2015 Authors